Search results
Results from the WOW.Com Content Network
Pellagra is a disease caused by a lack of the vitamin niacin (vitamin B 3). [2] Symptoms include inflamed skin, diarrhea, dementia, and sores in the mouth. [1] Areas of the skin exposed to friction and radiation are typically affected first. [1]
Defatting is the chemical dissolving of dermal lipids, from the skin, on contact with defatting agents. This can result in water loss from the affected area and cause the whitening and drying of the skin which may result in cracking, secondary infection and chemical irritant contact dermatitis. [1]
This page was last edited on 9 July 2021, at 03:43 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply ...
Likewise, sepsis and trauma are examples of foreign insults, [2] and encephalitis, multiple sclerosis, and brain tumors are examples of insults to the brain. [3] Clinicians may use the term cerebrovascular insult (CVI) as a synonym for a stroke. [4] [5] Insults may be categorized as either genetic or environmental. [6]
The dermatitis occurs on areas of skin exposed to sunlight, such as backs of hands and neck. Niacin deficiency is a consequence of a diet low in both niacin and the amino acid tryptophan, a precursor for the vitamin. Low plasma tryptophan is a non-specific indicator, meaning it can have other causes.
Riboflavin deficiency (also called ariboflavinosis) results in stomatitis, symptoms of which include chapped and fissured lips, inflammation of the corners of the mouth (angular stomatitis), sore throat, painful red tongue, and hair loss. [3] The eyes can become itchy, watery, bloodshot, and sensitive to light. [3]
The diagnosis is usually made by a brain scan , in which areas of swelling can be identified. The treatment for PRES is supportive: removal of the cause or causes and treatment of any of the complications, such as anticonvulsants for seizures. PRES may be complicated by intracranial hemorrhage, but this is relatively rare. The majority of ...
ARIA-E refers to cerebral edema, involving the breakdown of the tight endothelial junctions of the blood-brain barrier and subsequent accumulation of fluid. [3] In a double-blind trial of the humanised monoclonal antibody solanezumab (n = 2042), sixteen patients (11 taking the drug, 5 taking a placebo), or 0.78% developed ARIA-E.